Generated: May 30, 2017
|Title:||Gonadotropin releasing hormone antagonist|
|Abstract:||The present invention relates to a method to prevent a premature LH surge. The method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount between 0.125-1 mg in combination with exogenous FSH. The method can be used in the treatment of women undergoing controlled ovarian superovulation.|
|Inventor(s):||Mannaerts; Bernadette Maria Julia Louise (Acacialaan, NL), Coelingh Bennink; Herman Jan Tijmen (Melvill van Carnebeelaan, NL), Orlemans; Everardus Otto Maria (Wolvespoor, NL)|
|Assignee:||Akzo Nobel NV (Arnhem, NL)|
1. A method for attenuating LH rise in women undergoing controlled ovarian hyperstimulation by administering exogenous FSH, said method comprising administering cojointly FSH
and parenterally administering ganirelix in a daily dose of between 0.125 mg and 0.5 mg.
2. The method of claim 1, wherein the daily dose is 0.25 mg.
3. The method of claim 1, wherein said parenteral administration is subcutaneous.
4. The method of claim 1, wherein said ganirelix is is administered cojointly with FSH for 2-14 days.